Lipella Pharmaceuticals Inc. – NASDAQ:LIPO
Lipella Pharmaceuticals stock price today
Lipella Pharmaceuticals stock price monthly change
Lipella Pharmaceuticals stock price quarterly change
Lipella Pharmaceuticals stock price yearly change
Lipella Pharmaceuticals key metrics
Market Cap | 3.14M |
Enterprise value | 2.20M |
P/E | -4.4 |
EV/Sales | 10.14 |
EV/EBITDA | -0.98 |
Price/Sales | 32.88 |
Price/Book | 1.52 |
PEG ratio | 0.04 |
EPS | -0.77 |
Revenue | 210.99M |
EBITDA | -4.80M |
Income | -4.74M |
Revenue Q/Q | 23.57% |
Revenue Y/Y | 78320.29% |
Profit margin | -1894.89% |
Oper. margin | -1890.22% |
Gross margin | 0% |
EBIT margin | -1890.22% |
EBITDA margin | -2.28% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLipella Pharmaceuticals stock price history
Lipella Pharmaceuticals stock forecast
Lipella Pharmaceuticals financial statements
| Jun 2023 | 106.67M | -1.53M | -1.44% |
|---|---|---|---|
| Sep 2023 | 104.05M | -1.32M | -1.27% |
| Dec 2023 | 120.84K | -688.88K | -570.07% |
| Mar 2024 | 145.88K | -1.19M | -816.98% |
| 2025 | 535.16K | -1.68M | -314.08% |
|---|---|---|---|
| 2026 | 583.86K | -1.86M | -318.73% |
| 2027 | 636.98K | -1.92M | -301.57% |
| 2028 | 35.16M | 1.86M | 5.29% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3489536 | 364.19K | 10.44% |
|---|---|---|---|
| Sep 2023 | 2840945 | 619.21K | 21.8% |
| Dec 2023 | 3577174 | 432.72K | 12.1% |
| Mar 2024 | 3137157 | 575.87K | 18.36% |
| Jun 2023 | -655.10K | 0 | -250K |
|---|---|---|---|
| Sep 2023 | -689.36K | -14.43K | -2.28K |
| Dec 2023 | -730.05K | -14.41M | 1.61M |
| Mar 2024 | -1.38M | 0 | 200K |
Lipella Pharmaceuticals alternative data
| Aug 2023 | 5 |
|---|---|
| Sep 2023 | 5 |
| Oct 2023 | 5 |
| Nov 2023 | 5 |
| Dec 2023 | 5 |
| Jan 2024 | 5 |
| Feb 2024 | 5 |
| Mar 2024 | 5 |
| Apr 2024 | 5 |
| May 2024 | 5 |
| Jun 2024 | 5 |
| Jul 2024 | 5 |
Lipella Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 55000 | 0 |
| May 2024 | 10000 | 0 |
-
What's the price of Lipella Pharmaceuticals stock today?
One share of Lipella Pharmaceuticals stock can currently be purchased for approximately $0.59.
-
When is Lipella Pharmaceuticals's next earnings date?
Unfortunately, Lipella Pharmaceuticals's (LIPO) next earnings date is currently unknown.
-
Does Lipella Pharmaceuticals pay dividends?
No, Lipella Pharmaceuticals does not pay dividends.
-
How much money does Lipella Pharmaceuticals make?
Lipella Pharmaceuticals has a market capitalization of 3.14M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 144.15% to 449.62K US dollars.
-
What is Lipella Pharmaceuticals's stock symbol?
Lipella Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "LIPO".
-
What is Lipella Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lipella Pharmaceuticals?
Shares of Lipella Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Lipella Pharmaceuticals have?
As Jul 2024, Lipella Pharmaceuticals employs 5 workers.
-
When Lipella Pharmaceuticals went public?
Lipella Pharmaceuticals Inc. is publicly traded company for more then 2 years since IPO on 19 Dec 2022.
-
What is Lipella Pharmaceuticals's official website?
The official website for Lipella Pharmaceuticals is lipella.com.
-
Where are Lipella Pharmaceuticals's headquarters?
Lipella Pharmaceuticals is headquartered at 7800 Susquehanna St., Pittsburgh, PA.
-
How can i contact Lipella Pharmaceuticals?
Lipella Pharmaceuticals's mailing address is 7800 Susquehanna St., Pittsburgh, PA and company can be reached via phone at +41 28941853.
Lipella Pharmaceuticals company profile:
Lipella Pharmaceuticals Inc.
lipella.comNASDAQ
5
Biotechnology
Healthcare
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Pittsburgh, PA 15208
CIK: 0001347242
ISIN: US53630L1008
CUSIP: 53630L100
